Inclusion Criteria:

- Histologically confirmed and/or clinical and imaging evidence of a new brain mass
that is likely to be a supratentorial malignant glioma

- Clinical condition and physiologic status indicative of debulking surgery or biopsy
as standard initial therapy

- Performance status - Karnofsky performance status 60-100%

- WBC greater than 2,000/mm^3

- Platelet count greater than 90,000/mm^3

- Creatinine less than 2.0 mg/dL

- No significant cardiac condition that would preclude study therapy

- No symptomatic congestive heart failure

- No unstable angina pectoris

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for 1 month after study
completion

- Weight no greater than 130 kilograms

- No grade 3 or 4 peripheral neuropathy

- No other invasive malignancy within the past 3 years that is likely to cause a
solitary supratentorial metastasis

- No uncontrolled concurrent illness, medical condition, psychiatric illness, or social
situation that would preclude study participation

- At least 6 months since prior chemotherapy

- Concurrent corticosteroid therapy allowed

- At least 6 months since prior radiotherapy to lesion or site of lesion

- At least 6 months since prior surgery to lesion or site of lesion except incisional
or core biopsy

- Concurrent anticonvulsant therapy allowed

- No other concurrent investigational agents